MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 8.Navigating CLL Treatment Choices

EP: 9.Therapy Sequencing in CLL

Now Viewing

EP: 10.MCL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

EP: 11.MCL Therapy Selection and Sequencing

1. Provide an overview of the current landscape of induction therapies for MCL. What role do BTK inhibitors have in this landscape?
   1. Aggressive induction therapy

Related Videos